Is the metabolic dysfunction-associated steatotic liver disease a predictor of chronic kidney disease?

Figure 1 Flowchart assessment of patients with metabolic dysfunction-associated steatotic disease. The basic assessment helped differentiate patients into those with and without type-2 diabetes mellitus. Additionally, specific assessments exhibited a significant association between metabolic dysfunction-associated steatotic disease, diabetes mellitus, and increased chronic kidney disease stage. MASLD: Metabolic dysfunction-associated steatotic disease; DM: Diabetes mellitus; CKD: Chronic kidney disease; HOMA-IR: Homeostasis Model Assessment of Insulin Resistance.

Figure 2 Pathological degrees in patients and controls. A: Fibrosis-4 index and aspartate aminotransferase to platelet ratio index in patients and controls; B: Degree of fibrosis in patients and controls; C: Degree of steatosis in patients and control groups. MASLD: Metabolic dysfunction-associated steatotic disease; DM: Diabetes mellitus; F: Fibrosis; S: Steatosis; FIB-4: Fibrosis-4 index; APIR: Aspartate aminotransferase to platelet ratio index.